Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.
- P Olivera,
- W J Sandborn,
- J Panés,
- C Baumann,
- G D'Haens,
- S Vermeire,
- S Danese,
- L Peyrin-Biroulet
Aliment Pharmacol Ther 2018 Jan 19. Epub 2018 Jan 19.
INSERM U954 and Department of Hepatogastroenterology, Nancy University Hospital, Université de Lorraine, Vandoeuvre-lès-Nancy, France.
Background: Several novel compounds are being developed for inflammatory bowel diseases (IBD). In addition, biosimilar drugs are being approved. An increasing number of head-to-head, superiority and non-inferiority trials in patients with IBD are expected in the future. Read More